Review article : Psychopharmacological treatments for memory impairment

Miller E. Recovery and management of neuropsychological impairments. Chichester: Wiley, 1984: 117.

Ordy JM, Brizzee KR eds. Advances in behavioral biology. Neurobiol Aging 1975; 16.

Squire LR Mechanisms of memory. Science 1986; 232: 1612-19.

Cooper SJ Drug treatments, neurochemical change and human memory impairment. In: Wilson BA , Moffat N eds, Clinical management of memory problems. London: Croom Helm, 1984: 132-47.

Price DL , Whitehouse PJ , Struble RG et al. Basal forebrain cholinergic systems in Alzheimer's disease and related dementia. Neurosci Comm 1982; 1: 84-92.

Kopelman MD The cholinergic neurotransmitter system in human memory and dementia: a review . Q J Exp Psychol 1986; 4: 535-75.

Bowen DM , Smith CB , White P. , Davison AN Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 1976: 99: 459-96.

Davies P. , Maloney AJ Selective loss of central cholinergic neurones in Alzheimer's disease. Lancet 1976; ii: 1403.

Perry EK , Blessed G. , Tomlinson BE Necropsy evidence of central cholinergic deficits in senile dementia. Lancet 1977; i: 189.

Perry EK , Tomlinson BE , Blessed G. , Bergmann K. , Gibson PH , Perry RH Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br J Med 1978; 2: 1457-59.

Rossor M. , Fahrenkrug J. , Emson P. , Mountjoy C. , Iversen L. , Roth M. Reduced cortical choline acetyltransferase activity in senile dementia of Alzheimer type is not accompanied by changes in vasoactive intestinal polypeptide . Brain Res 1980; 201: 249-53.

Rossor MN , Garrett NJ , Johnson AL , Mountjoy CQ , Roth M. , Iversen LL A postmortem study of the cholinergic and GABA systems in senile dementia . Brain 1982; 105: 313-30.

Rossor MN , Iversen LL , Reynolds G. , Mountjoy CQ , Roth M. Neurochemical characteristics of early and late onset types of Alzheimer's disease. Br Med Bull 1984; 288: 961- 64.

McGeer EG , McGeer PL In: Ordy JM, Brizzee KR eds, Advances in behavioral biology. Neurobiol Aging 1975; 16: 287.

Carlsson A. , Adolfsson R. , Aquilonius SM et al. In: Goldstein M , Lieberman A , Calne DB , Thorner MO eds, Ergot compounds and brain function: neuroendocrine and neuropsychiatric aspects. New York: Raven, 1980.

Kopelman MD , Corn TH Cholinergic blockade as a model for cholinergic depletion. Brain 1988; 111: 1079-110.

Rusted JM , Warburton DM The effects of scopolamine on working memory in healthy young volunteers. Psychopharmacology 1988; 96: 145-52.

Preston GC , Brazell C. , Ward C. , Broks P. , Traub M. , Stahl SM The scopolamine model of dementia: determination of central cholinomimetic effects of physostigmine on cognition and biochemical markers in man. J Psychopharmacol 1988; 2: 67-79.

Anonymous. Drugs and memory (Editorial). Lancet 1982; i: 474-76.

Smith CM , Swash M. , Exton-Smith AN et al. Choline in Alzheimer's disease. Lancet 1978; i: 42.

Christie JE , Glen AI , Yates CM et al. Choline and lecithin effects on CSF choline levels and on cognitive function in Alzheimer pre-senile dementia. In: Glen AI , Whalley LJ eds, Alzheimer's disease. Edinburgh: Churchill Livingstone, 1979: 163-68.

Signoret JL , Whitely A. , Lhermitte F. Influence of choline on amnesia in early Alzheimer's disease. Lancet 1978; ii: 837.

Little A. , Levy R. , Chuaqui-Kidd P. , Hand D. A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1985 ; 48: 736-42.

Rossor MN , Iversen LL , Reynolds G. , Mountjoy CQ , Roth M. Neurochemical characteristics of early and late onset types of Alzheimer's disease. Br Med J 1984; 288: 961-64.

Bartus RT , Dean RL , Beer B. , Lippa AS The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408-17.

Christie JE , Shering DJ , Ferguson J. , Glen AI Physostigmine and arecoline: Effects of intravenous infusions in Alzheimer presenile dementia. Br J Psychiatry 1981; 138: 46-50.

Stone WS , Croul CE , Paul E. Attenuation of scopolamine-induced amnesia in mice. Psychopharmacology 1988; 96: 417-20.

Verloes R. , Scotto AM , Gobert J. , Wulfert E. Effects of nootropic drugs in a scopolamine-induced amnesia model in mice . Psychopharmacology 1988; 95: 226-30.

Johns CA , Greenwald BS , Mohs RC , Davis KL The cholinergic treatment strategy in ageing and senile dementia. Psychopharmacol Bull 1983; 19: 185-97.

Murray CL , Fibiger HC Pilocarpine and physostigmine attenuate spatial memory impairments produced by lesions of the nucleus basalis magnocellularis. Behav Neurosci 1986; 100: 23-32.

Bartus RT , Dean RL , Beer B. , Lippa AS The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408-17.

Bartus RT , Dean RL Tetrahydroaminoacridine, 3,4, diaminopyridine, and physostigmine: direct comparison of effects on memory in aged primates. Neurobiol Aging 1988; 9: 351-56.

Ordy JM , Thomas CJ , Volpe BT et al. An animal model of human-type memory loss based on aging, lesion, forebrain ischaemia, and drug studies with the rat. Neurobiol Aging 1988; 9: 667-83.

Smith CM , Swash M. Physostigmine in Alzheimer's disease. Lancet 1979; i: 42.

Ashford JW , Soldinger S. , Schaeffer J. , Cochran L. , Jarvik LF Physostigmine and its effects on six patients with dementia. Am J Psychiatry 1981; 138: 829-30.

Sullivan EV , Shedlack KJ , Corkin S. , Growdon JH Physostigmine and lecithin in Alzheimer's disease. In: Corkin S , Growdon JH , Usdin E , Wurtin RJ eds, Alzheimer's disease: a report on progress in research. Ageing, 19. New York: Raven Press.

Mohs RC , Davis BM , Johns CA et al. Oral physostigmine treatment of patients with Alzheimer's disease . Am J Psychiatry 1985; 142: 33-38.

Christie JE , Shering A. , Ferguson G. , Glen AI Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia. Br J Psychiatry 1981; 138: 46-50.

Davis KL , Mohs RC Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine. Am J Psychiatry 1982; 139: 1421-24.

Thal LJ , Fuld PA , Masur DM , Sharpless NS Oral physostigmine and lecithin improves memory in Alzheimer's disease. Ann Neurol 1983; 13: 491-96.

Muramato O. , Sugishita M. , Ando K. Cholinergic system and constructural praxis: a further study of physostigmine in Alzheimer's disease. J Neurol Neurosurg Psychiatry 1984; 47: 485-91.

Sahakian A. , Joyce E. , Lishman WA Cholinergic effects on constructional abilities and on mnemonic processes: a case report. Psychol Med 1987; 17: 329-33.

Thal LJ , Fuld PA Memory enhancement with oral physostigmine in Alzheimer's disease. N Engl J Med 1983; 308: 720.

Stern Y. , Sano M. , Mayeux R. Long-term administration of oral physostigmine in Alzheimer's disease. Neurology 1988; 38: 1837-41.

Beller SA , Overall JE , Rhoades HM , Swann AC Long-term outpatient treatment of senile dementia with oral physostigmine . J Clin Psychiatry 1988; 49: 400-404.

Summers WK , Viesselman JO , Marsh GM , Candelora K. Use of THA in treatment of Alzheimer-like dementia: pilot study in twelve patients. Biol Psychiatry 1981; 16: 145-53.

Summers WK , Majovski LV , Marsh GM , Tachiki K. , Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N Engl J Med 1986; 315: 1241-45.

Forsyth DR , Surmon DJ , Morgan RA , Wilcock GK Clinical experience and side effects of tacrine hydrochloride in Alzheimer's disease: a pilot study. Age Ageing 1989; 18: 223-29.

Marx JL Alzheimer's drug put on hold. Science 1987 ; 238: 1041-42.

Ames DJ , Bhatal PS , Davies BM , Fraser JR Hepatoxicity of THA. Lancet 1988; i: 887.

Pirozzolo FJ , Baskin DS , Swihart AA , Appel SH Oral tetrahydroaminoacridine in the treatment of senile dementia, Alzheimer's type. N Engl J Med 1987; 316: 1603.

Herrmann N. , Sadavoy J. , Steingart A. Oral tetrahydroaminoacridine in the treatment of senile dementia, Alzheimer's type. N Engl J Med 1987; 316: 1603-04.

Soni N. , Kam P. 4-aminopyridine - a review. Anaesth Intensive Care 1982; 10: 120-25.

Fanelli RJ , Rosenberg RA , Gallagher M. Role of noradrenergic function in the opiate antagonist facilitation of spatial memory. Behav Neurosci 1986; 100: 476-82.

Izquierdo I. , McGaugh JL Retention impairment by post-training epinephrine: role of state dependency and of endogenous opioid mechanisms. Behav Neurosci 1987; 101: 778-81.

Reisberg B. , Ferris SH , Anand R. , Mir P. , de Leon MJ , Roberts E. Naloxone effects on primary degenerative dementia (PDD). Psychopharmacol Bull 1983; 19: 44-47.

Reisberg B. , Ferris SH , Anand R. et al. Effects of naloxone in senile dementia: a double-blind trial. N Engl J Med 1983; 308: 721-22.

Blass JP , Reding MJ , Drachman D. et al. Naloxone in dementia. N Engl J Med 1983; 309: 556.

Panella JJ , Blass JP Lack of clinical benefit from naloxone in a dementia day hospital. Ann Neurol 1984; 15: 308.

Arnstein AF , Segal DS , Neville HJ et al. Naloxone augments electrophysiological signs of selective attention in man. Nature 1983; 304: 725-27.

Cohen RM , Cohen MR , Weingartner H. , Pickar P. , Murphy DC High-dose naloxone affects task performance in normal subjects. Psychiatry Res 1983; 8: 127-36.

Hyman BT , Eslinger PJ , Damasio AR Effect of naltrexone on senile dementia of the Alzheimer's type. J Neurol Neurosurg Psychiatry 1985; 48: 1169-71.

De Wied D. , Bohus B. Modulation of memory processes by neuropeptides of hypothalamic and neurohypophyseal origin. In: Brazier MA ed, Brain mechanisms in memory and learning: from the single neurone to man. New York: Raven Press, 1979: 139-50.

Lanfield PW , Sundberg DK , Smith MS , Eldridge JC , Movis M. Mammalian aging: theoretical implications of changes in brain and endocrine systems during mid- and late-life in rats . Peptides 1980; 1 (suppl): 185-96.

Martinez JL Jr , Vasquez BJ , Jensen RA , Soumireu-Mourat B. , McGaugh JL ACTH 4-9 analog (ORG 2766) facilitates acquisition of an inhibitory avoidance response in rats. Pharmacol Biochem Behav 1979; 10: 145-47.

Soumireu-Mourat B. , Micheau J. , Franc C. ACTH 4-9 analog (ORG 2766) and memory processes in mice. In: Martinez JL Jr , Jensen RA , Messing RN , Rigter H , McGaugh JL eds, Endogenous peptides and learning and memory processes. New York: Academic Press, 1981: 143-58.

Braverman A. , Hamdy R. , Meisner P. , Perera J. Clinical trial of Org 2766 (ACTH 4-9 analogue) in the treatment of elderly people with impaired mental function. In: Struwe G ed, 3rd World Congress of Biological Psychiatry, Stockholm: World Congress of Biological Psychiatry, 1981.

Walker B. , Sandman CA Influences of an analog of the neuropeptide ACTH 4-9 on mentally retarded adults. Am J Ment Defic 1979; 83: 346-52.

Wilner AE Influence of an analog of ACTH (Org 2766) on mood in elderly symptomatic volunteers . In: Struwe G ed, 3rd World Congress of Biological Psychiatry , Stockholm: World Congress of Biological Psychiatry, 1981.

De Wied D. , Versteeg HG Neurohypophyseal principles and memory. Fed Proc 1979; 38: 2348-58.

Messing RB , Sparber SB Greater task difficulty amplifies the effect of desglycinamide arginine vasopressin on appetitively motivated learning. Behav Neurosci 1985; 99: 1114-19.

Dantzer R. , Koob GF , Bluthe RM , le Moal M. Septal vasopressin modulates social memory in male rats. Brain Res 1988; 457: 143-47.

Weingartner H. , Gold P. , Ballenger JC et al. Effects of vasopressin on human memory functions. Science 1981; 211: 601-603.

Gold PW , Weingartner H. , Ballenger JC , Goodwin FK , Post RM Effects of 1-desamino-8-d-arginine vasopresin on behaviour and cognition in primary affective disorder. Lancet 1979; ii: 992-94.

le Boef A. , Lodge J. , Eames PG Vasopressin and memory in Korsakoff's syndrome. Lancet 1978; ii: 1370.

Oliveros JC , Jandali MK , Timsit-Berthier M. et al. Vasopressin in amnesia. Lancet 1978; i: 42.

Legros JJ , Gilot P. , Seron X. et al. Influence of vasopressin on learning and memory. Lancet 1978; i: 41-42.

Beckwith BE , Petros TV , Berghoff PJ , Staebler RJ Vasopressin analogue (DDAVP) facilitates recall of narrative prose. Behav Neurosci 1987; 101: 429-32.

Till RE , Beckwith BE Sentence memory affected by vasopressin analog (DDAVP) in cross-over experiment . Peptides 1985; 6: 397-402.

Millar K. , Jeffcoate WJ , Walder CP Vasopressin and memory: improvement in normal short-term recall and reduction of alcohol-induced amnesia. Psychol Med 1987 ; 17: 335-41.

Jenkins JS , Mather HM , Coughlan AK Effect of desmopressin on normal and impaired memory. J Neurol Neurosurg Psychiatry 1982; 45: 830-31.

Jenkins JS , Mather HM , Coughlan AK , Jenkins DG Desmopressin and desglycinamide vasopressin in post-traumatic amnesia. Lancet 1981; 1: 39.

Guard O. , Marchal G. , Graule A. , Dumas R. , D'Athis PL. Effects of vasopressin and desmopressin on memory. Neuropsychobiology 1986; 15: 80-83.

Jolles J. Vasopressin-like peptides and the treatment of memory disorders in man. Prog Brain Res 1983; 60: 169-82.

Kendall MJ Review of treatment in Alzheimer's disease. In: Markin JC , Rossor MN eds, Current approaches to Alzheimer's disease. Southampton : Inprint (Litho Ltd), 1987: 65-74.

Giurgea C. , Sara SJ Nootropic drugs and memory. In: Gruneberg MM , Morris PE , Sykes RN eds, Practical aspects of memory. London: Academic Press, 1978: 755-63.

Mindus P. et al. Does piracetam counteract the ECT-induced memory dysfunctions in depressed patients? Acta Psychiatr Scand 1975; 51: 319-26.

Ezzat DH , Ibraheem MM , Bouthayna M. The effect of piracetam on ECT-induced memory disturbances. Br J Psychiatry 1985; 147: 720-21.

Dilanni M. , Wilsher CR , Blank MS et al. The effects of piracetam in children with dyslexia. J Clin Psychopharmacol 1985; 5: 272-78.

Wilsher CR , Bennett D. , Chase CH et al. Piracetam and dyslexia: effects on reading tests. J Clin Psychopharrrcacol 1987; 7: 230-37.

Dimond SJ , Brouwers EY Increase in the power of memory in normal man through the use of drugs. Psychopharmacology 1976; 49: 307-309.

Dimond SJ Drugs to improve learning in man: implications and neuropsychological analysis . In: Knights RM , Bakker DJ eds, The neuropsychology of learning disorders , Baltimore: University Park Press , 1977.

Mindus P. , Cromholm B. , Levander SE , Schalling D. Piracetam-induced improvement of mental performance. Acta Psychiatr Scand 1976; 54: 150-60.

McDonald RJ Drug treatment of senile dementia. In: Wheatley D ed, Psychopharmacology of old age, Oxford: Oxford University Press, 1983.

Ferris SH , Reisberg B. , Crook T. et al. Pharmacologic treatment of senile dementia: choline, L-DOPA, piracetam, and choline plus piracetam. In: Corkin S , Davis KL , Growdon JH , Usdin E , Wurtman RJ , eds, Alzheimer's disease: a report of progress in research, New York: Raven Press, 1982; 164-68.

Growdon JH , Corkin S. , Huff FJ , Rosen TJ Piracetam with lecithin in the treatment of Alzheimer's disease. Neurobiol Aging 1986.